Large cell transformation (LCT) in mycosis fungoides (MF) is generally associated with an aggressive clinical course and poor survival, requiring aggressive therapeutic approach. However, a proportion of cases may follow an indolent clinical course. To identify prognostic factors we analyzed the prognostic relevance of clinical, histological and immunophenotypical features in a large cohort of transformed MF patients, including 75 patients with only skin lesions, 19 patients with LCT in skin and lymph nodes and 6 patients with LCT in lymph nodes only. Multivariate analysis of the total group showed that CD30 negativity, folliculotropic MF, extent of skin lesions and extracutaneous transformation were associated with reduced DSS and, except for CD30 negativity and folliculotropic MF, also OS. In a multivariate analysis of 75 patients with only skin lesions at the time of LCT, CD30 negativity, folliculotropic MF and extent of skin lesions were independent parameters for both DSS and OS. Using the most discriminating parameters as a prognostic index, in both study groups differences in DSS between patients with 0-1 unfavorable prognostic factor(s) and ≥ 2 unfavorable prognostic factors were statistically significant (p<0.001). This prognostic index may be helpful in predicting prognosis and selecting the most appropriate treatment in patients with transformed MF.
Introduction
Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma, clinically characterized by the slow progression from patches to plaques and in a proportion of patients to tumors. In a minority of patients dissemination to nodal and/or other extracutaneous sites may occur. While patients with early patch/plaque stage MF generally run an indolent course with a 10-year disease specific survival (DSS) over 80%, patients developing skin tumors or extracutaneous disease have a reduced 10-year DSS of 42% and less than 20%, respectively. 1;2 Apart from clinical stage, large cell transformation (LCT) in MF has been associated with an aggressive clinical course and a poor survival. [3] [4] [5] [6] [7] [8] [9] Most studies report a median survival between 2
and 36 months (Table 1) . Data on prognostic factors within these studies are however inconsistent and often conflicting, which probably relates to the small size of the groups studied thus far (12 to 45 patients; median 22 patients). Evaluation of these previous studies is further hampered by the inclusion of not only patients with MF, but also variable numbers of patients with Sézary syndrome (SS) in 5 of 7 studies, and by the variable proportions (17% to 92%) of patients with transformation at extracutaneous sites.
Remarkably, in a recent study of 1502 patients with MF/SS, including 70 patients with transformed MF at the time of first diagnosis, the median survival was 8.3 years and the 5-year overall and disease-specific survivals 63% and 65%, respectively. 1 Although not described in much detail, these survival data suggests a much better prognosis of transformed MF than reported in all previous studies (Table 1) .
In order to better define the prognosis and prognostic factors in patients with transformed MF, we evaluated the clinical, histological and immunophenotypical features of a large cohort of 100 transformed MF patients. This study reveals independent prognostic factors and provides a prognostic index, which may be helpful in the clinical management of patients with transformed
MF.
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Patients and methods

Patient selection
One hundred and thirty patients with a diagnosis of transformed MF or a histologic diagnosis of (early) blastic transformation were retrieved from the cutaneous lymphoma database of the Leiden University Medical Center (LUMC). For each case clinical records, skin biopsies (2 to 6 biopsies/case) and lymph node biopsies, if applicable, were reviewed. Hundred cases were included since they had clinical and histological features consistent with MF, and at least one biopsy showing LCT according to the criteria described previously: the presence of large T-cells exceeding 25% of the total lymphoid infiltrate or forming microscopic nodules. 4 This study group did not contain cases with coexisting lymphomatoid papulosis (LyP) or primary cutaneous anaplastic large cell lymphoma (C-ALCL).
In a previous study no difference in survival was found between patients presenting with tumor stage MF (stage IIB) with or without LCT. 10 For that reason 25 patients with stage IIB MF with LCT at first presentation, were compared with 27 patients presenting with stage IIB MF without LCT at first presentation, including 15 patients who developed LCT during follow-up and 12 patients who did not meet the criteria of LCT and were therefore excluded from the main study.
Clinicopathologic evaluation
All patients were classified according to the new criteria proposed by the ISCL and EORTC.
11
Staging included complete physical examination, blood cell count and chemistry, in most cases CT scan of abdomen, chest and (head and) neck (in case of head and/or neck lesions) and one or multiple skin biopsies. In all patients with clinically significant adenopathy a lymph node biopsy had been performed. stainings against T-cell antigens (CD2, CD3, CD4, CD5, CD8) , B-cell antigens (CD20, CD79a), histiocytes (CD68) and CD30 were studied to determine the phenotype of the atypical cells, to differentiate large T-cells from admixed histiocytes and to determine the percentage of large Tcells expressing CD30 (0-25%, 26-50%, 51-75% or >75%). In the MF stage IIB group without transformation only age, sex, folliculotropic MF, extent of skin lesions, duration of follow-up and survival status were recorded.
Prognostic factors
The following parameters were analyzed for their prognostic significance in transformed MF:
sex, age at diagnosis of LCT (≤60 yrs vs >60 yrs), time interval between MF and LCT (≤24 months after diagnosis MF vs >24 months after diagnosis MF), clinical stage at the time of LCT, folliculotropic MF, CD30 expression by more than 50% of the neoplastic T-cells and the extent of skin tumors. Extent of skin lesions was scored as solitary, regional (multiple skin lesions within one anatomic region) or generalized (multiple lesions in more than one anatomic region).
In a separate analysis of the 75 patients who presented with only skin lesions at the time of transformation the percentage of large T-cells (< 25% but clusters, 25-75% or >75%) was included in the analysis as well.
Statistical analysis
All statistical calculations were performed using SPSS version 17.0 (SPSS Inc, Chicago, IL). 
Results
Clinical characteristics and follow-up data
The main clinical and histological characteristics and follow-up data of the 100 patients with transformed MF are summarized in Table 2 . The study group included 64 males and 36 females (male-female ratio, 1.8:1), with a median age at transformation of 68 years (range 33-90 years). Table 2 , resulted in a complete remission in only 18 of 100 patients, which was however generally short-lived. Median survival after transformation was 24 months (range 1-235 months). DSS after 2, 5 and 10 years was 62%, 38% and 36%, respectively, and OS was 57%, 33% and 24%, respectively.
Histopathologic and immunophenotypical features
Biopsies from tumorous lesions generally showed a dense and diffuse infiltrate throughout the entire dermis, while the infiltrates in biopsies from patients with plaques stage (stage IB) disease were generally confined to the upper dermis. In this latter group three patients showed a predominantly intraepidermal accumulation of large CD30-positive (one case) or CD30-negative Table 2 .
Immunophenotypic analysis showed that 70 cases had a CD3+, CD4+, CD8-T-cell phenotype, 7 cases a CD3+, CD4-, CD8+ T-cell phenotype, and 19 cases a CD3+, CD4-, CD8-T-cell phenotype. In 4 cases the phenotype could not be assessed. In many cases there was (partial) loss of one or more pan-T-cell antigens, while 4 cases showed aberrant expression of CD20 and/or CD79a. CD30 was expressed by more than 75% of the large T-cells in 39 cases, by 50-75% in 8 cases, and between 5% and 20% in eight cases. In the other 45 cases CD30 staining was either completely negative or expressed by only very few (<5%) large T-cells.
Prognostic factors
In the total group of patients (n=100), both univariate and multivariate analysis established that extent of skin lesions, extracutaneous transformation, negative staining for CD30 and folliculotropic MF were associated with a reduced DSS (Table 3 ). Further analysis showed that the difference in survival between stage IB vs IIB was not significant, but that the differences between stage IV vs IIB and stage IV vs combined stage IB and IIB were significant for DSS (P=0.048 and P=0.018, respectively). Multivariate analysis for OS showed that extent of skin lesions and extracutaneous transformation, but not folliculotropic MF and CD30 negativity, were independent parameters for reduced OS (Table 3 ).
In the group with only transformation in skin lesions (stage IB-IIB; n=75) multivariate analysis showed that CD30 negativity, folliculotropic MF and extent of skin tumors were independent parameters for reduced DSS and OS (Table 4) . Further analysis showed no significant differences between solitary and regional skin tumors or between regional and generalized skin tumors.
However, patients with generalized skin tumors had a significantly worse DSS (P=0.005) and OS (P=0.002) when compared with the combined group of solitary and regional skin tumors. DSS curves of all independent parameters in the total group of patients (n=100) and in the patients with only skin lesions and LCT (n=75) are shown in Figure 1 .
Prognostic index
Since patients may have a combination of favorable and unfavorable prognostic factors, we developed a prognostic index, which may better predict prognosis and be an useful tool in For personal use only. on September 24, 2017. by guest www.bloodjournal.org From selecting appropriate treatment. For that purpose all independent prognostic factors for DSS were selected. For the total group of patients with transformed MF these were the presence of generalized skin lesions, extracutaneous transformation, CD30 negativity and folliculotropic MF.
Patients with 0 (16 cases), 1 (36 cases), 2 (31 cases), 3 (14 cases) or 4 (3 cases) unfavorable prognostic factors had a 2-year DSS of 83%, 85%, 52%, 14% and 33%, respectively. Sub analysis showed that the difference in DSS between the 52 patients with 0-1 unfavorable prognostic factor and the 48 patients with 2-4 unfavorable prognostic factors was statistically significant (P<0.001; Figure 2A ). For the group of patients with only transformed skin lesions CD30 negativity, folliculotropic MF and the presence of generalized skin lesions were selected.
Patients with 0 (14 cases), 1 (33 cases), 2 (21 cases) or 3 (7 cases) unfavorable prognostic factors had a 5-year DSS of 73%, 61%, 19% and 0%, respectively. The difference in DSS between the 47 patients with 0-1 unfavorable prognostic factor and the 28 patients with 2-3 unfavorable prognostic factors was statistically significant (P<0.001; Figure 2B ).
Comparison between patients with tumor stage MF (stage IIB) with or without transformation at first presentation.
While transformed MF is generally associated with a poor prognosis, in a previous study no difference in survival was found between patients with stage IIB with or without LCT at the time of first presentation. 10 In our study 65 patients had stage IIB at time of transformation. Within this group, 25 patients had LCT at first presentation. These 25 patients were compared 27 patients with stage IIB MF without LCT at first presentation. Differences in DSS and OS between both groups were statistically not significant (Table 5 ). Further analysis between those patients who presented with stage IIB without LCT, but developed LCT during follow-up (n=15) and those patients who did never develop LCT (n=12), also showed no statistically significant differences in survival (data not shown).
For
Discussion
Previous studies demonstrated that LCT in MF is associated with an aggressive clinical course and a poor survival. [3] [4] [5] [6] [7] [8] [9] 13 Notwithstanding, in the last 20 years we have regularly seen MF patients with transformation in skin and even lymph node biopsies, who after treatment followed an indolent course for many years. This is reflected in the present study, in which 23 of 100 patients, 
Advanced stage at transformation
Several studies reported that patients with extracutaneous transformation have a shorter median survival than patients with transformation limited to the skin. 3;4 In contrast, in the study of Diamandidou no difference in survival was found between patients with cutaneous and 7 In fact, patients with transformed stage IIB (tumor stage) did as poorly as or even worse than patients with extracutaneous transformation (stage IV). Patients with transformed stage I-IIA (plaques) did significantly better than the combined transformed IIB-IV groups. In the present study more advanced stage was significantly associated with reduced survival (Table 3 ). Sub analysis showed that extracutaneous transformation (stage IV) had a significantly poorer survival than cutaneous disease transformation (combined IB-IIB vs IV, P=0.018). No significant difference in survival was found between stage IB and stage IIB, indicating that extracutaneous transformation is the main factor responsible for shorter survival.
CD30 expression
Several studies have suggested that CD30 expression in transformed MF may be associated with a better prognosis. 5, 6, 9 However, in none of the published studies a significant difference between CD30-positive and CD30-negative cases was found, which is probably due to the small size of the study groups. In the present study CD30 expression proved a strong and independent predictor of improved survival, both in the total group of patients and in patients with Table 2 ). However, none of our patients had a chronic recurrent selfhealing papulonodular eruption consistent with LyP. In all CD30+ cases, a diagnosis of C-ALCL was unlikely, since 1) tumors developed in areas with preexistent patches or plaques, 2) showed an admixture with small to medium sized atypical T-cells with cerebriform nucles (characteristic of MF) and/or 3) showed significant folliculotropism, which is rarely seen in cases of C-ALCL. Although it cannot be excluded completely, we do not believe our study contained patients with combined MF and C-ALCL.
Folliculotropic MF
The significance of folliculotropic MF in the prognosis of transformed MF has not been studied in previous studies. Although included as a distinct variant of MF in recent classifications for cutaneous lymphomas, cases of folliculotropic MF were included in the present study to allow 1 1 comparison with previously published series. Both in the total group and in patients with transformation in only skin lesions folliculotropic MF was a strong and independent predictor of reduced survival. Similarly, in other studies on large cohorts of MF patients folliculotropic MF was associated with a poorer survival.
1;2
Extent of skin tumors
In the group with transformation only in skin lesions we investigated the prognostic significance of the extent of transformed skin lesions. It must be emphasized that transformation was generally demonstrated in only one lesion, assuming that other, clinically similar lesions, showed the same histology. The presence of generalized skin tumors was strongly associated with reduced DSS and OS, when compared with the combined group of solitary and localized skin tumors. However, no significant differences were found between solitary and localized skin tumors or between localized and generalized skin tumors.
Percentage of blast cells
Progression from plaque to tumor stage MF is accompanied by a gradual increase of blast cells and a decrease of atypical T-cells with cerebriform nuclei and of inflammatory cells, and associated with a reduced prognosis. One might therefore expect that high percentages of blast cells (>75%), reflecting further tumor progression, are associated with a worse prognosis.
However, no association between the percentage of blast cells and survival was found which is consistent with the results of a previous study. 9 Also, when stratified for CD30 expression an association was not found (data not shown).
In conclusion, previous studies of transformed MF emphasized above all the aggressive clinical behavior and poor prognosis of these patients. 14 Second, though the median and 5-year survival in the present study were similar to that of previous studies, the results of this study clearly demonstrate that not all patients with transformed MF run an aggressive clinical course. The prognostic index described herein may be a valuable tool to predict which patients will have an aggressive and which a more indolent clinical course, and may aid to select the most appropriate treatment in patients with transformed MF. However, the applicability and usefulness of this new tool needs to be validated by future studies.
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